CN106692111A - External skin patch containing ketoprofen and preparation method of external skin patch - Google Patents
External skin patch containing ketoprofen and preparation method of external skin patch Download PDFInfo
- Publication number
- CN106692111A CN106692111A CN201510776173.7A CN201510776173A CN106692111A CN 106692111 A CN106692111 A CN 106692111A CN 201510776173 A CN201510776173 A CN 201510776173A CN 106692111 A CN106692111 A CN 106692111A
- Authority
- CN
- China
- Prior art keywords
- patch
- ketoprofen
- weight
- sis
- patch according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses an external skin patch containing ketoprofen. An adhesive layer of the patch consists of 10-50wt% of a styrene-isoprene-styrene segmented copolymer (SIS), 5-30wt% of tackifying resin and 19.9-59.9wt% of a softening agent, with 1-5wt% of ketoprofen serving as an active ingredient, wherein the tackifying resin is not selected from rosin resins. The external skin patch provided by the invention can effectively solve the problems of a ketoprofen local analgesic patch which is easy for crystallization, low in drug-loading capacity, complex in production process, easy for peeling, low in percutaneous penetration rate and the like; and the finally obtained external ketoprofen local analgesic patch is free from crystallization, high in drug-loading capacity, rapid to take effects, free from a peeling phenomenon when attached to skin, good in practicability and low in side effects.
Description
Technical field
The present invention relates to field of medicine preparations, in particular to a kind of skin external used patch containing Ketoprofen and preparation method thereof.
Background technology
Ketoprofen（Ketoprofen）, chemical name 2-（3- benzoylphenyls）Propionic acid, belongs to phenylpropionic acid NSAIDs, and its main mechanism is reversible inhibition epoxidase and lipoxygenase, so as to suppress the biosynthesis of Prostaglandins and Leukotrienes, plays antipyretic, analgesia and antiinflammatory action, also there is maincenter analgesic effect.Clinic is mainly used in treating various arthritis, postoperative pain and chronic cancer pain etc..Ketoprofen is insoluble in water, it is distributed mainly on after gastro-intestinal administration in stomach, small intestine, kidney, so larger to the stimulation of intestines and stomach, clinically major side effects to have a stomach-ache, heartburn sense, nausea,vomiting,diarrhea, constipation, poor appetite, weakness etc., there is hemorrhage of gastrointestinal tract in a small amount of patient.Used as NSAIDs, its curative effect is better than brufen to Ketoprofen, but because its oral formulations adverse reaction is larger, limits its clinical practice, therefore exploitation novel form turns into the new problem that people solve the problems, such as Ketoprofen clinical practice.
Transdermal delivery system（Transdermal drug delivery system, abbreviation TDDS）The novel formulation of percutaneous dosing is meant, through percutaneous drug delivery, drugs through skin reaches effective blood drug concentration and is transferred to diseased region by capillary absorbance into blood circulation, plays a part of Prevention locally or systemically disease, and its form of administration is generally patch（Patch）.Not only targeting is good patch, it is to avoid the first pass effect of liver, improves bioavilability；But also lasting, constant and controllable blood concentration can be produced, and administration number of times and dosage are reduced, it is discontinued at any time, so as to mitigate adverse reaction.
In recent years, people have carried out numerous studies to the external skin administration patch of Ketoprofen.Chinese patent CN97120585, CN99806963.9,
CN99808428 describes the local topical patch of NSAIDs, but for patch permeability and tack the problems such as fail to propose effective solution, meanwhile, when paster drugloading rate is increased, there is crystallization in patch, has a strong impact on the use of the therapeutic effect and patient of paster.CN01808284 discloses the anti-inflammatory agent patch without MENTHOL,First,Menthol can play synergy over the course for the treatment of with anti-inflammatory agent,Promote the absorption of medicine,So that medicine rapid-onset,Inapplicable menthol can cause that the drug effect of patch is substantially reduced,Secondly,Described in the invention containing using polyphosphazene polymer isobutene and low molecular weight polycaprolactone butylene and rosin resinoid in anti-inflammatory medicine plaster preparation process,Two kinds of proterties of polyisobutene are the high auxiliary material of class solid stickiness,Requirement to being weighed in preparation process is high,It is not easy to operate,And rosin resinoid is the tackifier commonly used in patch,But it can promote bulk drug in lotion to be permeated to back sheet,Reduce the drug effect of lotion,Again,Rosin resinoid is used alone in preparation can make darkening for colloid,And there is certain volatility in heating process in rosin resinoid,Its stability is difficult to control to,Therefore realize that industrialized production is more difficult,Finally,The tack of rosin resin is poor,Sample peeling after often fitting.CN03129630 discloses the transdermal patch prepared using hot-fusible pressure-sensitive adhesive, but to prepare and need high-temperature heating in such patch, under the high temperature conditions the easy decomposition failure of Ketoprofen.
The content of the invention
Not enough for more than, researcher of the present invention has found by further investigation, with SIS（SIS）, tackifying resin, in softening agent and transdermal enhancer in preparation of the menthol as required composition, rosin resinoid is not contained in tackifying resin wherein, the present invention is patch thickening type resin from alicyclic saturated hydrocarbon resin, the menthol for promoting drug effect is added simultaneously, technical solution of the present invention not only can effectively suppress crystallization, suppress infiltration of the bulk drug to back sheet, improve lotion content of dispersion, improve the bioavilability of patch, and the technical program can effectively solve Ketoprofen local analgesia patch complex production process, it is easily peelable, the low problem of patch percutaneous rate, finally obtain without crystallization, drugloading rate is big, it is rapid-action, skin attachement is without peeling, practicality is good, the Ketoprofen local analgesia external use plaster of Small side effects.
For achieving the above object, present invention employs following technical scheme：
A kind of skin external used patch containing Ketoprofen, the patch contains back sheet, medicine storing layer, adhesive phase, adherent layer, and wherein adhesive phase contains SIS（SIS）10~50 weight %, the weight % of tackifying resin 5~30 and the weight % of softening agent 19.9~59.9, active ingredient are the weight % of Ketoprofen 1~5,.
Part of the invention is stopped in logical patch, and the consumption of the Ketoprofen contained as active ingredient is 1~5 weight %, preferably 1~3 weight %.If consumption is very few, absolute release amount of medicine is reduced, it is impossible to which the possibility that obtaining has desired part to stop logical effect becomes big.After consumption is excessive more preferable drug release rate can not be reached because Ketoprofen starts precipitation crystallization.Additionally, the unnecessary increase of preparation of traditional Chinese medicine concentration not only results in adhesion decline, and side effect can be produced to skin.
Specifically, the matrix components for being used in local analgesia patch of the invention are SIS（SIS）, usage amount is 10~50 weight %, preferably 20~40 weight %.Usage amount is very few, then the cohesive force of matrix is not enough when i.e. less than 10 weight %, there can be the problem of pastel residual in skin surface after patch is peeled off, undesirable, additionally, using it is excessive when, as consumption is too high more than the cohesive force of matrix in the case of 50 weight %, product is really up to the mark, and adhesion declines, and kneading operation can be caused difficult.
The tackifying resin for using in local analgesia patch of the invention is mixed with matrix, assigns material of the matrix to the adhesiveness of skin, may be selected from Petropols, alicyclic saturated hydrocarbon resin, and wherein tackifying resin is not selected from rosin resinoid.If being added without tackifying resin, without adhesiveness, without the function of attaching.In the present invention, in order to disperse Ketoprofen, make patch that there is certain adhesiveness simultaneously, we preferably use alicyclic saturated hydrocarbon resin, consumption is 5~30 weight %, 15~25 weight % are preferably used, adhesiveness is not enough when consumption is too small, and adhesiveness is excessive when consumption is excessive causes physical stimulation to skin.
Softening agent in local analgesia patch of the invention, may be selected from one or more in paraffin class oil, silicone oil, higher fatty acids, vegetable oil, and its consumption is 19.9~59.9 weight %, preferably 29.9~59.9 weight %.If lotion is really up to the mark when consumption is very few, the trackability to skin is poor, cannot be adapted to the adhesion of skin, and patch is easily peeled off, and the cohesive force of adhesive can be destroyed when consumption is excessive, causes paster degradation or has pastel to remain.
If it is necessary, adhesive phase can also add transdermal enhancer, antioxidant, filler, tackifier and other pharmaceutically acceptable excipient in external use plaster of the invention.Wherein transdermal enhancer may be selected from menthol, Laurocapram, azone, laurate, oleic acid, N, N- dimethyl acetic acid dodecanes ester, N, one or more in N- dimethyl isopropyl acid dodecanes ester, METHYLPYRROLIDONE, 1- butyl -3- dodecyls -2-Pyrrolidone.Antioxidant may be selected from butylhydroxy seedling perfume ether（BHA）, dibutyl hydroxy toluene（BHT）, the vinegar of gallic acid third（PG）, TBHQ（TBHQ）In one or more, preferred dibutyl hydroxy toluene（BHT）.Filler may be selected from one or more in zinc stearate, titanium dioxide, silica, zinc oxide, calcium carbonate, kaolin, Avobenzone.Tackifier may be selected from polybutene, polyphosphazene polymer isobutene, preferably low molecular polyisobutylene, polybutene.
Verified usual in external preparation patch, the flexibility of backing, retractility can influence the trackability to skin, and have much relations with the improvement of percutaneous drug absorption.In external use plaster of the invention, flexibility and retractility backing high are preferably used, may be selected from non-woven fabrics or looped fabric.
Adherent layer in external use plaster of the invention may be selected from polyethylene terephthalate（PET）, polypropylene（PP）, separate paper, preferably polyethylene terephthalate（PET）.
A kind of preparation method of skin external used patch containing Ketoprofen that the present invention is provided, it is as follows：
（1）
Main ingredient is dissolved in softening agent and stirs to form suspension；
（2）
The mixture of addition SIS, antioxidant and filler and other compositions, heating for dissolving is uniformly mixed, and adds tackifier, stirs；
（3）
After after the cooling of above-mentioned lotion, main ingredient solution and transdermal enhancer are added, stirred；
（4）
Gained ointment-containing body is uniformly coated on the adherent layer treated through silicon, after being fitted as the back sheet of preparation, the size and dimension of setting is cut into, you can local analgesia external use plaster of the invention is obtained.
Brief description of the drawings
Fig. 1 is the accumulative transdermal release curve of Ketoprofen patch.
Fig. 2 is the In-vitro release curves of Ketoprofen patch.
Specific embodiment
With reference to specific embodiment, the present invention is expanded on further.But these embodiments are only limitted to the explanation present invention rather than limitation the scope of the present invention.The experimental technique of unreceipted specific experiment condition in the following example, generally according to normal condition, or according to the condition proposed by manufacturer.
Embodiment
1
Preparation method：4.0g Ketoprofens are dissolved in atoleine and stir to form suspension.By 40g SISs, 1.0g Avobenzones, 16g polybutene, 0.2g zinc stearates, 1.0g BHT heating for dissolving, it is uniformly mixed, add 36.0g KE-311, stir, after after lotion cooling, add ketoprofen solution, add 4.0g menthols, 4.0g azones, stir, gained ointment-containing body is uniformly coated on the adherent layer treated through silicon, after being fitted as the back sheet of preparation, the size and dimension of setting is cut into, you can obtain local analgesia external use plaster of the invention.
Embodiment
2
In addition to above-mentioned formula, other make patch similarly to Example 1.
Embodiment
3
In addition to above-mentioned formula, other make patch similarly to Example 1.
Embodiment
4
In addition to above-mentioned formula, other make patch similarly to Example 1.
Embodiment
5
In addition to above-mentioned formula, other make patch similarly to Example 1.
Embodiment
6
In addition to above-mentioned formula, other make patch similarly to Example 1.
Embodiment
7
In addition to above-mentioned formula, other make patch similarly to Example 1.
Embodiment
8
In addition to above-mentioned formula, other make patch similarly to Example 1.
Embodiment
9
In addition to above-mentioned formula, other make patch similarly to Example 1.
Embodiment
10
In addition to above-mentioned formula, other make patch similarly to Example 1.
Comparative example
1
In addition to above-mentioned formula, other make patch similarly to Example 1.
Comparative example
2
In addition to above-mentioned formula, other make patch similarly to Example 1.
Comparative example
3
Preparation method：4.0g Ketoprofens are dissolved in atoleine and stir to form suspension.By 82g SISs, 1.0g Avobenzones, 0.2g zinc stearates, 1.0g BHT, 8.0g polyphosphazene polymer isobutenes, 8.0g low molecular polyisobutylene heating for dissolving, it is uniformly mixed, add 24g terpene resins, 8g hydrogenated rosin resins, stir, after after lotion cooling, add ketoprofen solution, add 3.8g menthols, stir, gained ointment-containing body is uniformly coated on the adherent layer treated through silicon, after being fitted as the back sheet of preparation, it is cut into the size and dimension of setting, local analgesia external use plaster of the invention can be obtained.
Comparative example
4
Reference
CN01808284
Preparation method：The SIS of formula ratio, polyphosphazene polymer isobutene, low molecular polyisobutylene, rosin resinoid, atoleine, zinc stearate are made mixture, heating stirring is into dissolved matter under the inert atmospheres such as nitrogen, it is subsequently added into Ketoprofen, stir to obtain homogeneous dissolved matter, the dissolved matter is directly extended to after support puts on, after covering covering is peeled off, desired shape is cut into.
Embodiment
11
Vitro skin bleed through test
-Strat-
Membrane
Experiment
Patch obtained by the embodiment of the present invention 1 ~ 10 and comparative example 1 ~ 4 is tested by the following method：
Sample patch is cut into suitable area to be affixed on apery skin Strat- Membrane films, is fixed between diffusion cell two upper and lower chambers, cuticula is upward（Donor side）.The built-in magnetic stirrer of reception tank, add pH5.8 isotonic phosphate buffer liquid, by in vitro transdermal device in 37 DEG C of water-baths, start the stirring of magnetic stirring apparatus constant speed, acceptable solution is sampled in 1,2,3,4,5,6,9,12,18,24h different time points, the amount of the Ketoprofen that apery skin Strat- Membrane films are passed through is determined by HPLC methods.
The embodiment 1-10 of table 1 and the accumulative transdermal release degree result of comparative example 1-4 Ketoprofens
The result of table 1 shows, Ketoprofen patch percutaneous rate prepared by the present invention is higher, and faster, drug effect is fast for release, while drug transdermal concentration is high, can effective therapy-related inflammation.
Test example
12
Vitro release is tested
Using the present invention, by embodiment 1 ~ 10 and obtained in comparative example 1 ~ 4, Ketoprofen patch is tested by the following method.
Take this product 1, remove adherent layer, with it is two-sided it is gluing with net dish on, glue surface upward, according to drug release determination method（Chinese Pharmacopoeia version two in 2010）Using pH5.8 PBSs 900ml as dissolution medium, rotating speed is 50 turns per minute, 37 DEG C of bath temperature, 10ml is sampled respectively at 0.5,1,2,3,4,5,6,8,10,12,18,24h, and mutually synthermal, same volume dissolution medium is supplemented simultaneously, and take out sample release solution and filtered with 0.45 μm of miillpore filter, subsequent filtrate is taken as test sample solution.The accumulative releasing degree of Ketoprofen is determined by HPLC methods.
The releasing result of the embodiment 1-10 of table 2 and comparative example 1-4 Ketoprofen patches
The result of table 2 shows, Ketoprofen patch prepared by the present invention can quick release, the action speed of medicine is effectively improved, while hereafter, drug release profiles are steady, and drug concentration reaches stable state, can improve internal bioavilability.
The stability test of embodiment 12 is studied
To patch is obtained in embodiment 1~10 and comparative example 1 ~ 4 severe cruel experiment is carried out respectively (60 DEG C ± 2 DEG C, RH75% ± 5%) investigates the stability of preparation, as a result as shown in table 3.The assay method of stability：According to《Chemicals stability study technological guidance's principle》Write with Chinese Pharmacopoeia Commission《Chinese Pharmacopoeia two annex of version in 2005 (XIX C)》In test method in " medicine stability test guideline " take this product simulation listing packaging (being encapsulated into Aluminum-plastic composite bag with medicinal drier after aluminum-plastic packaged), it is placed in 60 DEG C ± 2 DEG C, continuous placement 0,7,14,21 days samples in RH75% ± 5%, HPLC methods determine the content of main ingredient in preparation, as a result as shown in table 3.
Severe cruel experiment (60 DEG C ± 2 DEG C, RH75% ± 5%) of patch prepared by the embodiment 1~10 of table 3 and comparative example 1 ~ 4
Percentage sign in table 3 represents percentage composition of the Ketoprofen relative to input Ketoprofen in patch.Patch stability prepared by the result of table 3 present invention is higher, and content of dispersion is significantly higher than comparative example in patch, and patch volume of the invention can more effectively suppress crystallization, keep the content of dispersion of patch, can more effectively improve bioavilability, improve therapeutic effect.
The present invention is describe in detail above by reference to specific embodiment, to those skilled in the art, it should be appreciated that above-mentioned specific embodiment is not construed as limiting the scope of the present invention.Therefore, embodiment of the present invention can made various changes and modifications without departing from the spirit and scope of the present invention.
Claims (10)
1. a kind of skin external used patch containing Ketoprofen, the patch contains back sheet, medicine storing layer, adhesive phase and adherent layer, and wherein adhesive phase contains SIS（SIS）10~50 weight %, the weight % of tackifying resin 5~30 and the weight % of softening agent 19.9~59.9, active ingredient are the weight % of Ketoprofen 1~5.
2. patch according to claim 1, it is characterised in that active ingredient Ketoprofen consumption preferably 1~3 weight %, SIS is preferred（SIS）20~40 weight %, tackifying resin preferably 15~25 weight %, softening agent preferably 29.9~59.9 weight %, wherein adhesive phase can also add transdermal enhancer, antioxidant, filler, tackifier and other pharmaceutically acceptable excipient, wherein tackifying resin is not selected from rosin resinoid, and menthol is contained in transdermal enhancer.
3. the patch according to claim 1, it is characterised in that tackifying resin may be selected from one or two in Petropols, alicyclic saturated hydrocarbon resin, preferably alicyclic saturated hydrocarbon resin.
4. patch according to claim 1, it is characterised in that softening agent may be selected from one or more in paraffin silicone oil, silicone oil, higher fatty acids, vegetable oil.
5. patch according to claim 2, it is characterized in that transdermal enhancer may be selected from menthol, Laurocapram, azone, laurate, oleic acid, N, N- dimethyl acetic acid dodecanes ester, N, one or more in N- dimethyl isopropyl acid dodecanes ester, METHYLPYRROLIDONE, 1- butyl -3- dodecyls -2-Pyrrolidone.
6. patch according to claim 2, it is characterised in that antioxidant may be selected from butylhydroxy seedling perfume ether（BHA）, dibutyl hydroxy toluene（BHT）, the vinegar of gallic acid third（PG）, TBHQ（TBHQ）In one or more, preferred dibutyl hydroxy toluene（BHT）.
7. patch according to claim 2, it is characterised in that filler may be selected from one or more in zinc stearate, titanium dioxide, silica, zinc oxide, calcium carbonate, kaolin, Avobenzone；Tackifier may be selected from polybutene, polyphosphazene polymer isobutene, preferably low molecular polyisobutylene, polybutene.
8. the patch according to claim 1, it is characterised in that back sheet may be selected from non-woven fabrics or looped fabric.
9. the patch according to claim 1, it is characterised in that adherent layer may be selected from polyethylene terephthalate（PET）, polypropylene（PP）, separate paper, preferably polyethylene terephthalate（PET）.
10. a kind of preparation method of the skin external used patch containing Ketoprofen, as follows：
(1) main ingredient is dissolved in softening agent and stirs to form suspension；
(2) mixture of addition SIS, antioxidant and filler and other compositions, heating for dissolving is uniformly mixed, and adds tackifier, stirs；
(3) after after the cooling of above-mentioned lotion, main ingredient solution and transdermal enhancer are added, is stirred；
(4) gained ointment-containing body is uniformly coated on the adherent layer treated through silicon, after being fitted as the back sheet of preparation, is cut into the size and dimension of setting, you can obtain local analgesia external use plaster of the invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510776173.7A CN106692111A (en) | 2015-11-13 | 2015-11-13 | External skin patch containing ketoprofen and preparation method of external skin patch |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510776173.7A CN106692111A (en) | 2015-11-13 | 2015-11-13 | External skin patch containing ketoprofen and preparation method of external skin patch |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106692111A true CN106692111A (en) | 2017-05-24 |
Family
ID=58931257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510776173.7A Pending CN106692111A (en) | 2015-11-13 | 2015-11-13 | External skin patch containing ketoprofen and preparation method of external skin patch |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106692111A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114588133A (en) * | 2022-03-14 | 2022-06-07 | 南方医科大学深圳医院 | An oxycodone-containing topical analgesic patch for skin and its preparation method |
| CN117159508A (en) * | 2023-09-18 | 2023-12-05 | 湖南九典制药股份有限公司 | Hot-melt patch and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1087515A (en) * | 1992-12-03 | 1994-06-08 | 久光制药株式会社 | Inflammation diminishing and pain easing plaster and manufacture method thereof |
| CN1424908A (en) * | 2000-04-18 | 2003-06-18 | 久光制药株式会社 | Patch containing anti-inflammatory agent |
| JP2004115417A (en) * | 2002-09-25 | 2004-04-15 | Nichiban Co Ltd | Adhesive tape type antiphlogistic sedative patch |
| CN1565523A (en) * | 2003-07-03 | 2005-01-19 | 上海现代药物制剂工程研究中心 | Percutaneous plaster and its preparation method |
| TW200520793A (en) * | 2003-12-26 | 2005-07-01 | Hisamitsu Pharmaceutical Co | Anti-infammatory adhesive preparations |
| CN101370487A (en) * | 2005-10-24 | 2009-02-18 | 株式会社太平洋 | Transdermal preparations containing hydrophobic non-steroidal anti-inflammatory drugs |
| CN102370631A (en) * | 2011-11-08 | 2012-03-14 | 北京泰德制药股份有限公司 | Cutaneous external patch for treating dysmenorrhea |
-
2015
- 2015-11-13 CN CN201510776173.7A patent/CN106692111A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1087515A (en) * | 1992-12-03 | 1994-06-08 | 久光制药株式会社 | Inflammation diminishing and pain easing plaster and manufacture method thereof |
| CN1424908A (en) * | 2000-04-18 | 2003-06-18 | 久光制药株式会社 | Patch containing anti-inflammatory agent |
| JP2004115417A (en) * | 2002-09-25 | 2004-04-15 | Nichiban Co Ltd | Adhesive tape type antiphlogistic sedative patch |
| CN1565523A (en) * | 2003-07-03 | 2005-01-19 | 上海现代药物制剂工程研究中心 | Percutaneous plaster and its preparation method |
| TW200520793A (en) * | 2003-12-26 | 2005-07-01 | Hisamitsu Pharmaceutical Co | Anti-infammatory adhesive preparations |
| CN101370487A (en) * | 2005-10-24 | 2009-02-18 | 株式会社太平洋 | Transdermal preparations containing hydrophobic non-steroidal anti-inflammatory drugs |
| CN102370631A (en) * | 2011-11-08 | 2012-03-14 | 北京泰德制药股份有限公司 | Cutaneous external patch for treating dysmenorrhea |
Non-Patent Citations (1)
| Title |
|---|
| 罗明生，等: "《药物辅料大全》", 31 January 2006, 四川出版集团 四川科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114588133A (en) * | 2022-03-14 | 2022-06-07 | 南方医科大学深圳医院 | An oxycodone-containing topical analgesic patch for skin and its preparation method |
| CN117159508A (en) * | 2023-09-18 | 2023-12-05 | 湖南九典制药股份有限公司 | Hot-melt patch and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW411277B (en) | Percutaneous tape preparation containing fentanyl | |
| JPH1135458A (en) | Diclofenac sodium-containing oily plaster preparation for external use | |
| CN102413821A (en) | Transdermal preparation | |
| WO2005077364A1 (en) | Transdermal solifenacin preparation and method of improving transdermal permeability thereof | |
| JPH0747535B2 (en) | Anti-inflammatory analgesic patch | |
| WO2006092829A1 (en) | External plaster containing flurbiprofen | |
| JP2006206471A (en) | Tape preparation | |
| TW201438767A (en) | Compositions and methods for transdermal delivery of non-steroidal anti-inflammatory agents | |
| JPH10218793A (en) | Percutaneous absorption type adhesive tape for anti-inflammation and analgesic and its production | |
| WO2007077741A1 (en) | Transdermally absorbable preparation | |
| JPS63246327A (en) | Plasta containing etofenamate | |
| CN106692111A (en) | External skin patch containing ketoprofen and preparation method of external skin patch | |
| JP2001097852A (en) | Plaster for external use | |
| JPH04178323A (en) | Pharmaceutical preparation for percutaneous administration | |
| JP3276188B2 (en) | Patch and method for producing the same | |
| JPH04217919A (en) | Percutaneously eperisone or tolperisone-absorbing preparation | |
| JP2002516879A (en) | Composition for transdermal administration of non-steroidal anti-inflammatory analgesic | |
| CN104173322A (en) | Piroxicam-containing transdermal-absorption preparation and preparation method thereof | |
| AU723018B2 (en) | Base composition for percutaneous absorption and percutaneously absorbable preparation containing the base composition | |
| TW201223528A (en) | Transdermal absorption preparation | |
| CA2800716C (en) | Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith | |
| JP2004131495A (en) | Pharmaceutical composition for topical application containing nonsteroidal anti-inflammatory | |
| WO2001001990A1 (en) | Adhesive preparation for percutaneous absorption | |
| CN109432061A (en) | Multilayer transdermal delivery system containing brufen or its analogue | |
| WO2018198029A1 (en) | Matrix adhesive patch and process for the preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170524 |